Analyst Price Targets — LYEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 9, 2025 11:14 am | — | H.C. Wainwright | $45.00 | $28.36 | TheFly | Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright |
| November 24, 2025 11:15 am | — | H.C. Wainwright | $20.00 | $19.13 | TheFly | Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright |
| October 30, 2024 6:05 am | Geoff Meacham | Bank of America Securities | $1.00 | $0.95 | TheFly | Lyell Immunopharma downgraded to Underperform from Buy at BofA |
| November 14, 2022 6:18 am | — | Morgan Stanley | $7.00 | $4.53 | Benzinga | Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7 |
| May 24, 2022 10:09 am | — | Goldman Sachs | $12.00 | $4.01 | Benzinga | Goldman Sachs Maintains Buy on Lyell Immunopharma, Lowers Price Target to $12 |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for LYEL

Stock News U.S. pump prices jump on war-driven supply shock: Average U.S. gasoline rose to about $3.54/gal, the highest since midâ2024, as the U.S.âIran con

Stock News Oil pulls back from $100+: Brent fell roughly 8% toward $91 as President Trump indicated the Iran conflict could end âvery soon,â while Saudi Ara

SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100…

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LYEL.
U.S. House Trading
No House trades found for LYEL.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
